STOCKHOLDERS EQUITY (Tables)
|
6 Months Ended |
Jun. 30, 2021 |
|---|
| STOCKHOLDERS' EQUITY [Abstract] |
|
| Schedule of Assumptions |
The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2021 and
2020:
| |
Six Months Ended June 30,
|
| |
2021
|
|
2020
|
|
Expected term
|
5.5 - 6.3 years
|
|
5.5 - 6.3 years
|
|
Volatility
|
69%
|
|
62-67%
|
|
Dividend yield
|
0.0
|
|
0.0
|
|
Risk-free interest rate
|
0.80-1.14%
|
|
0.38-1.68%
|
|
| Schedule of Option Activity |
A summary of the Company’s option activity under the 2007 Plan and 2014 Plan and related information is as
follows:
| |
|
Shares
|
|
|
Weighted
Average
Exercise Price
|
|
|
Options outstanding, vested and expected to vest at December 31, 2020
|
|
|
6,922,931
|
|
|
$
|
4.40
|
|
|
Forfeited
|
|
|
(404,782
|
)
|
|
$
|
2.96
|
|
|
Expired
|
|
|
(393,170
|
)
|
|
$
|
5.03
|
|
|
Granted
|
|
|
1,658,050
|
|
|
$
|
2.26
|
|
|
Exercised
|
|
|
-
|
|
|
$
|
-
|
|
|
Options outstanding, vested and expected to vest at June 30, 2021
|
|
|
7,783,029
|
|
|
$
|
3.98
|
|
| |
|
|
|
|
|
|
|
|
|
Options exercisable
|
|
|
5,011,506
|
|
|
$
|
4.70
|
|
|
| Schedule of Unvested RSU Activity |
A summary of the Company’s unvested RSU activity and related information is as follows:
| |
|
Shares
|
|
|
Weighted
Average Grant
Date Fair Value
|
|
|
Balance at December 31, 2020
|
|
|
326,000
|
|
|
$
|
2.81
|
|
|
Granted
|
|
|
542,244
|
|
|
$
|
2.29
|
|
|
Vested
|
|
|
(87,750
|
)
|
|
$
|
2.81
|
|
|
Forfeited
|
|
|
(94,361
|
)
|
|
$
|
2.53
|
|
|
Balance at June 30, 2021
|
|
|
686,133
|
|
|
$
|
2.44
|
|
|
| Schedule of Stock-Based Compensation Expense |
Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for
the three months and six months June 30, 2021 and 2020 is as follows:
| |
|
Three Months Ended June 30,
|
|
|
Six Months Ended June 30,
|
|
| |
|
2021
|
|
|
2020
|
|
|
2021
|
|
|
2020
|
|
|
Research and development
|
|
$
|
42,479
|
|
|
$
|
105,029
|
|
|
$
|
147,706
|
|
|
$
|
198,603
|
|
|
Plasma center operating expenses
|
|
|
13,637
|
|
|
|
8,510
|
|
|
|
24,455
|
|
|
|
15,754
|
|
|
Selling, general and administrative
|
|
|
665,836
|
|
|
|
539,256
|
|
|
|
1,254,327
|
|
|
|
1,063,145
|
|
|
Cost of product revenue
|
|
|
83,237
|
|
|
|
62,813
|
|
|
|
160,098
|
|
|
|
114,654
|
|
|
Total stock-based compensation expense
|
|
$
|
805,189
|
|
|
$
|
715,608
|
|
|
$
|
1,586,586
|
|
|
$
|
1,392,156
|
|
|